{"organizations": [], "uuid": "270eb3f08c43185e9d82c312df7910ee60affb2f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/johnsonjohnson-fda/fda-approves-jj-prostate-cancer-treatment-idUSL4N1Q45QR", "country": "US", "domain_rank": 408, "title": "FDA approves J&J prostate cancer treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.546, "site_type": "news", "published": "2018-02-15T02:48:00.000+02:00", "replies_count": 0, "uuid": "270eb3f08c43185e9d82c312df7910ee60affb2f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/johnsonjohnson-fda/fda-approves-jj-prostate-cancer-treatment-idUSL4N1Q45QR", "ord_in_thread": 0, "title": "FDA approves J&J prostate cancer treatment", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "patrick graham", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "johnson & johnson", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "j&j", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnsonâ€™s Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.\nThe drug is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, the FDA said in a statement. (Reporting by Manas Mishra in Bengaluru; editing by Patrick Graham)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T02:48:00.000+02:00", "crawled": "2018-02-15T20:23:59.001+02:00", "highlightTitle": ""}